CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. O'Shaughnessy, J., Piccart, M., Schwartzberg, L. S., Cortes, J., Harbeck, N., Im, S., Rugo, H. S., Untch, M., Yardley, D. A., Bondarenko, I., Chan, S., Dieras, V., Pegram, M. D., Kroll, S., O'Connell, J. P., Vacirca, J., Wei, T., Tang, K., Seidman, A. AMER SOC CLINICAL ONCOLOGY. 2019

View details for DOI 10.1200/JCO.2019.37.15_suppl.TPS1107

View details for Web of Science ID 000487345803227